Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

M.H.G. Langenberg; P.O. Witteveen; J.M.L. Roodhart; H.M.W. Verheul; M. Mergui-Roelvink; J. van der Sar; E. Brendel; N. Laferriere; J.H.M. Schellens; E.E. Voest

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

M.H.G. Langenberg
, P.O. Witteveen
, J.M.L. Roodhart
, H.M.W. Verheul
, M. Mergui-Roelvink
, J. van der Sar
, E. Brendel
, N. Laferriere
, J.H.M. Schellens
, E.E. Voest

Clinical Pharmacology

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2187-2197
Number of pages	11
Journal	Clinical Cancer Research
Volume	16
Issue number	7
Publication status	Published - 2010

Cite this

Langenberg, M. H. G., Witteveen, P. O., Roodhart, J. M. L., Verheul, H. M. W., Mergui-Roelvink, M., van der Sar, J., Brendel, E., Laferriere, N., Schellens, J. H. M., & Voest, E. E. (2010). Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clinical Cancer Research, 16(7), 2187-2197.

@article{b0de588fec55430f8ceb8c4e4abf98c1,

title = "Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors",

author = "M.H.G. Langenberg and P.O. Witteveen and J.M.L. Roodhart and H.M.W. Verheul and M. Mergui-Roelvink and \{van der Sar\}, J. and E. Brendel and N. Laferriere and J.H.M. Schellens and E.E. Voest",

year = "2010",

language = "English",

volume = "16",

pages = "2187--2197",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

Langenberg, MHG, Witteveen, PO, Roodhart, JML, Verheul, HMW, Mergui-Roelvink, M, van der Sar, J, Brendel, E, Laferriere, N, Schellens, JHM & Voest, EE 2010, 'Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors', Clinical Cancer Research, vol. 16, no. 7, pp. 2187-2197.

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. / Langenberg, M.H.G.; Witteveen, P.O.; Roodhart, J.M.L. et al.
In: Clinical Cancer Research, Vol. 16, No. 7, 2010, p. 2187-2197.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

AU - Langenberg, M.H.G.

AU - Witteveen, P.O.

AU - Roodhart, J.M.L.

AU - Verheul, H.M.W.

AU - Mergui-Roelvink, M.

AU - van der Sar, J.

AU - Brendel, E.

AU - Laferriere, N.

AU - Schellens, J.H.M.

AU - Voest, E.E.

PY - 2010

Y1 - 2010

M3 - Article

SN - 1078-0432

VL - 16

SP - 2187

EP - 2197

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -